Diagnostic method for biomarkers of adverse coronary events
Patent 8137978 Issued on March 20, 2012. Estimated Expiration Date: October 16, 2029. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
A diagnostic method using biomarkers to predict future adverse coronary events is provided. More particularly, the present invention is directed to diagnostic tests for characterizing an individual's risk of developing or having cardiovascular disease. In certain embodiments, the method of the present invention quantitates the presence of elevated levels of chlorinated lipids derived from myeloperoxidase as a prognostic indicator of future adverse coronary events.
Ma et al., Amer. Heart Assoc., vol. 114(11) (2006).
Nguyen et al., J. Physiol, vol. 565(2), pp. 403-413 (2005).
McCabe, J. Ped Surgery, vol. 36(2), pp. 334-337 (Feb. 2001).
Pol et al., J. Neuro. Anethesiology, vol. 4(1), pp. 26-30 (1992).
X. Fu, S.Y. Kassim, W.C. Parks, J.W. Heineck, Hypocholorous Acid Generated by Myeloperoxidase Modifies Adjacent Tryptophan and Glycine Residues in the Catalytic Domain of Matrix Metalloproteinase-7 (Matrilysin): An Oxidative Mechanism for Restraining Proteolytic Activity During Inflammation, Journal of Biological Chemistry, 2003, 28403-28409, vol. 278.
Stephan Baldus, MD, Christopher Heeschen, MD, Thomas Meinertz, MD, Andreas M. Zeiher, MD, Jason P. Eiserich, PhD, Thomas Munzel, MD, Maarten L. Simoons, MD, Christian W. Hamm, MD, Myeloperoxidase Serum Levels predict Risk in Patients with Acute Coronary Syndromes, Retrieved from www.circulationaha.org, Jul. 10, 2003, 1440-1445, USA.
Seigo Sugiyaman, Yoshikatsu Okada, Galina K. Sukhova, Renu Virmani, Jay W. Heinecke, Peter Libby, Macrophage Myecloperoxidase Regulation by Granulocyte Macrophage Colony-Stimulating Factor in Human Atherosclerosis and Implications in Acute Coronary Syndromes, American Journal of Pathology, Mar. 2001, v. 158, No. 3, USA.
S.S. Bassuk, N. Rifai, P.M. Ridker, High-sensitivity C-reactive Protein: Clinical Importance, Current Problems in Cardiology, 2004, 439-493, vol. 29.
Renliang Zhang, Md, PhD, Marie-Luise Brennan, PhD, Ziaoming Fu, MS, Ronnier J. Aviles, MD, Gregory L. Pearce, MS, Marc S. Penn, MD, PhD, Eric J. Topol, MD, Dennis L. Sprecher, MD, Stanley L. Hazen, MD, PhD, Association Between Myeloperoxidase Levels and Risk of Cornoary Artery Disease, Journal of American Medical Association, Nov. 7, 2001, 2136-2142, v. 286, No. 17, USA.
Ramachandran S. Vasan, MD., Biomarkers of Cardiovascular Disease Molecular Basis and Practical Considerations, Circulation, 2006, 2335-2362, retrieved from www.circulationaha.org, USA.
R. Vlaicu, H.G. Rus, F. Niculescu, A. Cristea, Immunoglobulins and Complement Components in Human Aortic Atherosclerotic Intima, Atherosclerosis, 1985, 35-50, vol. 55.
R. Pecoits-Filho, P. Stenvinkel, A. Marchlewska, O. Heimburger, P. Barany, C. M. Hoff, C. J. Holmes, M. Suliman, B. Lindholm, M. Schalling, L. Nordfors, A Functional Variant of the Myeloperoxidase gene is Associated with Cardiovascular Disease in End-Stage Renal Disease Patients, Kidney International- Supplement, 2003, s172-176.
Paul M. Ridker, Role of inflammatory biomarkers in prediction of coronary heart disease, The Lancet, Sep. 22, 2001, 946-948, vol. 358, USA.
Michelle A. Albert, Ellie Danielson, Nader Rifai, Paul M. Ridker, Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evalution (Prince): A Randomized Trial and Cohort Study, Journal of American Medical Association, Jul. 4, 2001, 64-74, vol. 286, No. 1, retrieved Jun. 25, 2009 from www.jama.com.
Maria C. Messner, Carolyn J. Albert, David A. Ford, 2-Cholorhexadecanal and 2-Cholorhexadecanoic Acid Induce COX-2 Expression in Human Coronary Artery Endothelial Cells, LIPDS, Mar. 11, 2008, 8 pgs, AOCS, Springer.
Kristin R. Wildsmith, Carolyn J. Albert, Dhanalakshmi S. Anbukumar, David A. Ford, Metabolism of Myeloperoxidase-derived 2-Chlorohexadecanal, Journal of Biological Chemistry, Jun. 23, 2006, 16849-16860, v. 281, No. 25, USA.
Kristin R. Wildsmith, Carolyn J, Albert, Dhanalakshmi S. Anbukumar, David A. Ford, Metabolism of Myeloperoxidase-derived 2-Chlorohexadecanal, The Journal of Biological Chemistry, Jun. 23, 2006, 16849-16850, vol. 281, No. 25, USA.
John Danesh, Rory Collins, Paul Appleby, Richard Peto, Association of Figrinogen, C-reactive Protein, Albumin, or Leukocyte Count with Coronary Heart Disease, Journal of American Medical Association, May 13, 1998, 1477-1482, vol. 279, No. 18, retrieved Jun. 25, 2009 from www.jama.com.
I.J. Kullo, G.T. Gau, A.J. Tajik, Novel Risk Factors for Atherosclerosis, Mayo Clinic Proceedings, 2000, 369-380, vol. 75.
G.D. Reynolds and R.P. Vance, C-reactive Protein Immunohistochemical Localization in Normal and Atherosclerotic Human Aortas, Archives of Pathology & Laboratory Medicine, 1987, 265-269, vol. 111.
D. Kutter, P. Devaquet, G. Vanderstocker, J.M. Paulus, V. Marchal, A. Gothot, Consequences of Total and Subtotal Mywloperoxidase Deficiency: Risk or Benefit?, Acta Haematologica, 2000, 10-15, vol. 104.
Cem Gabay, MD and Irving Kushner, MD, Acute-phase Proteins and Other Systemic Responses to Inflammation, The New England Journal of Medicine, Feb. 11, 1999, 448-454, vol. 340, No. 6, USA.
Carolyn J. Albert, Jan R. Crowley, Fong-Fu Hsu, Arun K. Thukkani, David A. Ford, Reactive Chlorinating. Species Produced by Myeloperoxidase Target the Vinyl Ether Bond of Plasmalogens, The Journal of Biological Chemistry, Jun. 29, 2001, 23733-23741, v. 276, No. 26, USA.
Baohai Shao, Abderrazzaq Belaaouaj, Christophe L. M. J. Verlinde, Xiaoyun Fu, Jay W. Heinecke, Methionine Sulfoxide and Proteolytic Cleavage Contribute to the Inactivation of Cathepsin G by Hypochlorous Acid, The Journal of Biological Chemistry, Aug. 12, 2005, 29311-29321, vol. 280, No. 32, USA.
B Nikppor, G Turecki, C Fournier, P. Theroux, G.A. Rouleau, A Functional Myeloperoxidase Polumorphic Variatn is Associated with Coronary Artery Disease in French-Canadians, American Heart Journal, 2001, 336-339, vol. 142.
Arun K. Thukkani, Jane McHowat, Fong-Fu Hsu, Marie-Luise Brennan, Stanley L. Hazen, David A. Ford, Identification of a-Chloro Fatty Aldehydes and Unsaturated Lysophosphatidylcholine Molecular Species in Human Atherosclerotic Lesions, Circulation, Aug. 18, 2003, 3128-3133, retrieved from www.circulationaha.org, USA.
Arun K. Thukkani, Fong-Fu Hsu, Jan R. Crowley, Robert B. Wysolmerski, Carolyn J. Albert, David A. Ford, Reactive Chlorinating Species Produced During Neutrophil Activation Target Tissue Plasmalogens, The Journal of Biological Chemistry, Feb. 8, 2002, 3842-3849, v. 277, No. 6, USA.
Arun K. Thukkani, Carolyn J. Albert, Kristin R. Wildsmith, Maria C. Messner, Bradley D. Martinson, Fong-Fu Hsu, David A. Ford, Myeloperoxidase-derived Reactive Chloinating Species from Human Monocytes Target Plasmalogens in Low Density Lipoprotein, The Journal of Biological Chemistry, Sep. 19, 2003, 36365-36372, v. 278, No. 38, USA.
Arun K. Thukkani, Bradley D. Martinson, Carolyn J. Albert, George A. Vogler, David A. Ford, Neutrophil-mediated accumulation of 2-CIHDA during myocardial infarction: 2-CIDHA-mediated myocardial injury, American Journal of Physiology, Jan. 28, 2005, H2955-H2964, vol. 288, USA.
Antonino Buffon, MD, Luigi M. Biasucci, MD, Giovanna Liuzzo, MD, Giuseppe D'Onofrio, MD, Filippo Crea, MD, Attilio Maseri, MD, Widespread Coronary Inflammation in Unstable Angine, The New England Journal of Medicine, Jul. 4, 2002, 5-12, vol. 347, No. 1, USA.
Albert et al. Journal of Chromatography B, vol. 877, 2009, pp. 2768-2777.
Albert et al. The Journal of Biological Chemistry, vol. 277, No. 7, Feb. 15, 2002, pp. 4694-4703.